Alert detail
FDA Approval: EMGALITY (GALCANEZUMAB-GNLM) — Type 1 - New Molecular Entity
Policy ID: FDA-BLA761063Specialty: NeurologyAdded: 6/10/2026Effective: 2018-09-27billing update
Full alert analysis requires a subscription
Subscribe to access the complete alert summary, AI-generated action recommendations, source document links, LCD revision comparisons, and related alerts.